Get the StoQuant digest — free
Free StoQuant digest by email. No account needed.
See today's research picks.
ASND vs GMAB — Stock Comparison
Compare ASND and GMAB side-by-side on StoQuant: ASND Q-Score 50 vs GMAB 50; analyst signal 67 vs 50. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- ASND — Ascendis Pharma A/S · Health Care · market cap $13.83B · Q-Score verdict Hold (50.0, grade C) · analyst signal 67/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: ML forecast 56/100, technicals 56/100 · weakest signals: analyst consensus 49/100, valuation 48/100. Full ASND research.
- GMAB — Genmab A/S · Health Care · market cap $22.13B · Q-Score verdict Unrated (50.0) · analyst signal 50/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: ML forecast 79/100, technicals 63/100 · weakest signals: analyst consensus 15/100. Full GMAB research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: ASND research · GMAB research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →